Magle Chemoswed Holding AB (FRA:52X) ROCE % : 7.92% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Magle Chemoswed Holding AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Magle Chemoswed Holding AB's annualized ROCE % for the quarter that ended in Mar. 2024 was 7.92%.

Magle Chemoswed Holding AB ROCE % Historical Data

The historical data trend for Magle Chemoswed Holding AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Magle Chemoswed Holding AB ROCE % Chart

Magle Chemoswed Holding AB Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

1.45

2.35

3.79

6.32

8.95

Magle Chemoswed Holding AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															8.41	12.27	2.89	12.25	7.92

Magle Chemoswed Holding AB ROCE % Calculation

Magle Chemoswed Holding AB's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	1.636	/	( ( (23.001 - 4.747)	+	(24.403 - 6.11) )	/ 2 )
	=	1.636	/	( (18.254	+	18.293)	/ 2 )
	=	1.636	/	18.2735
	=	8.95 %

Magle Chemoswed Holding AB's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	1.468	/	( ( (24.403 - 6.11)	+	(25.687 - 6.917) )	/ 2 )
	=	1.468	/	( ( 18.293	+	18.77 )	/ 2 )
	=	1.468	/	18.5315
	=	7.92 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Magle Chemoswed Holding AB (FRA:52X) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Magle Chemoswed Holding AB ROCE % Related Terms

Thank you for viewing the detailed overview of Magle Chemoswed Holding AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Magle Chemoswed Holding AB (FRA:52X) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Magle Chemoswed Holding AB (FRA:52X) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

MAGLE:Sweden

Address

Agneslundsvagen 27, Malmo, SWE, 21215

Website

https://www.maglechemoswed.com

Magle Chemoswed Holding AB is a contract development and manufacturing organization that serves companies in the pharmaceutical and medical device industry on a contract basis. It provides comprehensive services from product development through product manufacturing. The company's products portfolio includes Warfarin sodium, Melperone hydrochloride, Isradipine, Amantadine sulfate, and Benserazide hydrochloride.

Magle Chemoswed Holding AB (FRA:52X) Headlines

No Headlines